Company · NVO
Novo Nordisk
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
20
16 still marketed
Novel approvals
6
Approvals since 2021
8
Originals and new uses
Phase 3 trials
365
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Awiqli Flextouch new use Priority reviewOct 23, 2026
- Awiqli Flextouch approved NovelOrphanMar 26, 2026
- Sogroya new use Feb 27, 2026
- Sogroya new use Feb 27, 2026
- Sogroya new use Feb 27, 2026
- Alhemo approved OrphanJul 31, 2025
- Alhemo approved NovelPriority reviewOrphanDec 20, 2024
- Sogroya new use Apr 28, 2023
- Sogroya approved NovelAug 28, 2020
- Rybelsus approved Jan 16, 2020
Drugs in development (21)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- matched to NNC0487-0111Phase 39 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- FT-4202EtavopivatPhase 36 trials
Forma Therapeutics, Inc. · Sickle Cell Disease, Thalassemia
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- NNC6019-0001Phase 33 trials
Novo Nordisk · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Insuline glargine U100reduced, titratedPhase 32 trials
Ascentage Pharma Group Inc. · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy, Diabetes Mellitus, Type 2
- matched to semaglutidePhase 32 trials
Novo Nordisk · Overweight, Obesity, Diabetes Mellitus, Type 2
- matched to zenagamtidePhase 32 trials
Novo Nordisk · Overweight, Obesity
- SemagludtidePhase 32 trials
Lumos Pharma · Obesity & Overweight, Early Alzheimer's Disease
- matched to CagrilintidePhase 31 trial
Novo Nordisk · Overweight, Obesity, Type 2 Diabetes
- NNC0519-0130Phase 23 trials
Novo Nordisk · Chronic Kidney Disease, Diabetes Mellitus, Type 2, Obesity
- NNC0662-0419Phase 23 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Overweight
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
- NNC0194-0499Phase 22 trials
Novo Nordisk · Alcohol-related Liver Disease, Non-alcoholic Steatohepatitis
- NNC0662-3168Test product-APhase 21 trial
Novo Nordisk · Overweight, Obesity, Type 2 Diabetes Mellitus
- TrizepatidePhase 21 trial
Novo Nordisk · Diabetes Mellitus, Type 2
Recruiting Phase 3 trials
Largest first.
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07567001 · 5,610 participants (planned) · Start May 11, 2026 · Primary completion Jul 23, 2029
Drug: NNC0487-0111; Placebo · For: Obesity; Heart Failure
Sites: Alexander City, Alabama; Birmingham, Alabama; Fairhope, Alabama · 838 sites in all
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07564414 · 2,500 participants (planned) · Start May 21, 2026 · Primary completion Feb 23, 2028
Drug: Cagrisema; Semaglutide · For: Obesity; Type 2 Diabetes
Sites: Birmingham, Alabama; Pelham, Alabama; Gilbert, Arizona · 303 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07797335 · 1,778 participants (planned) · Start Aug 24, 2026 · Primary completion Jul 31, 2028
Drug: Zenagamtide; Insulin glargine U-100 · For: Type 2 Diabetes; Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Montgomery, Alabama · 330 sites in all
- CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07207811 · 1,280 participants (planned) · Start Oct 2, 2025 · Primary completion Jun 29, 2029
Drug: NNC6019-0001; Placebo (NNC6019-0001) · For: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 299 sites in all
- AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07339423 · 1,150 participants (planned) · Start Feb 24, 2026 · Primary completion Jun 26, 2029
Drug: NNC0487-0111; Placebo (matched to NNC0487-0111) · For: Obesity
Sites: Miramar, Florida; Orlando, Florida; Conyers, Georgia · 72 sites in all
- AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07720271 · 950 participants (planned) · Start Aug 31, 2026 · Primary completion Jun 27, 2028
Drug: zenagamtide; Placebo · For: Overweight; Obesity
Sites: Anniston, Alabama; Birmingham, Alabama; Montgomery, Alabama · 41 sites in all
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutidePivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07668414 · 650 participants (planned) · Start Sep 22, 2026 · Primary completion Oct 10, 2028
Drug: Zenagamtide; Semaglutide and 2 more · For: Overweight; Obesity
Sites: Lancaster, California; Palm Springs, California; Pomona, California · 45 sites in all
- A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseasePivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06612268 · 510 participants (planned) · Start Feb 17, 2025 · Primary completion Aug 27, 2027
Drug: Etavopivat; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 175 sites in all
- A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or ThalassaemiaPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06609226 · 480 participants (planned) · Start Jan 10, 2025 · Primary completion Dec 30, 2030
Drug: Etavopivat A; Etavopivat B and 1 more · For: Sickle Cell Disease; Thalassemia
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 107 sites in all
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07253285 · 460 participants (planned) · Start Jan 8, 2026 · Primary completion Mar 20, 2030
Drug: Cagrilintide; Semaglutide and 2 more · For: Overweight; Obesity
Sites: Escondido, California; Hollywood, Florida; Jacksonville, Florida · 121 sites in all
Marketed drugs (16)
Newest FDA action first.
- Awiqli Flextouch Insulin Icodec · 2026
- Sogroya Somapacitan-Beco · 2020
- Victoza Liraglutide · 2010
- Alhemo Concizumab · 2025
- Alhemo Concizumab-Mtci · 2024
- Norditropin Flexpro Somatropin · 2000
- Vagifem Estradiol · 1999
- Novolog Penfill Insulin Aspart Recombinant · 2000
- Novolog Mix 70/30 Penfill Insulin Aspart Protamine Recombinant, Insulin Aspart Recombinant · 2001
- Levemir Flextouch Insulin Detemir Recombinant · 2005
- Novolin 70/30 Insulin Recombinant Human, Insulin Susp Isophane Recombinant Human · 1991
- Novolin N Insulin Susp Isophane Recombinant Human · 1991
- Novolin R Insulin Recombinant Human · 1991
- Rybelsus Semaglutide · 2020
- Activella Estradiol, Norethindrone Acetate · 2006
- Levemir Insulin Detemir · 2005
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.